Avastin Secures Japanese Approval For Colorectal Cancer
This article was originally published in The Pink Sheet Daily
Biologic approved under country’s recently initiated “fast regulatory” program.
You may also be interested in...
Similar to Genentech’s price cap on Avastin in the U.S., Roche is evaluating “creative” pricing approaches following breast cancer approval.
Genentech/Roche’s Avastin, however, could be the first biologic to gain approval for the indication in Japan.
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.